Incruse Ellipta: Indications for Use
Incruse Ellipta (umeclidinium bromide) is a once-daily long-acting muscarinic antagonist (LAMA) indicated for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. 1
Primary Indication
Incruse Ellipta is approved by the FDA specifically for COPD maintenance therapy, not for asthma or acute bronchospasm. 1
- Umeclidinium is a long-acting muscarinic antagonist (anticholinergic) that provides 24-hour bronchodilation with once-daily dosing 1
- It is delivered through the novel Ellipta dry powder inhaler device, which offers single-step activation and improved ease of use 1, 2
Clinical Context and Positioning
COPD Treatment Algorithm
For patients with moderate to severe COPD requiring maintenance bronchodilator therapy:
- Monotherapy option: Umeclidinium can be used as a single long-acting bronchodilator for patients not adequately controlled on short-acting bronchodilators 1
- Combination therapy: Umeclidinium is also available combined with vilanterol (a long-acting beta-agonist) as Anoro Ellipta for dual bronchodilation 1
- Triple therapy: For patients requiring inhaled corticosteroids, umeclidinium/vilanterol can be combined with fluticasone furoate in Trelegy Ellipta 1
Important Distinctions
Incruse Ellipta is NOT indicated for:
- Asthma treatment (asthma requires inhaled corticosteroids as foundation therapy) 1
- Acute relief of bronchospasm or acute exacerbations 1
- Initial treatment of acute episodes of COPD 1
Key Clinical Considerations
Patient Selection Criteria
Appropriate candidates for Incruse Ellipta include:
- Adults with confirmed COPD diagnosis requiring maintenance bronchodilator therapy 1
- Patients seeking once-daily dosing convenience to improve adherence 1
- Those who can generate adequate inspiratory flow (≥30 L/min) through the dry powder inhaler 2
Critical Safety Points
Do not use Incruse Ellipta in combination with other anticholinergic medications to avoid duplication of therapy and increased anticholinergic side effects 1
Common anticholinergic adverse effects include:
- Dry mouth
- Urinary retention (particularly in men with prostatic hyperplasia)
- Narrow-angle glaucoma exacerbation
- Constipation 1
Device Characteristics
The Ellipta device offers practical advantages:
- Three simple steps: open, inhale, close 2
- Over 97% of patients can correctly use the device without error 2
- Consistent dose delivery at flow rates ≥30 L/min 2
- 30-day shelf life once opened 2
Evidence Base
The 2015 American College of Chest Physicians and Canadian Thoracic Society guidelines identified umeclidinium as a novel once-daily LAMA approved for COPD that offers adherence advantages through simplified dosing 1. The 2023 Canadian Thoracic Society guidelines further support the use of long-acting muscarinic antagonists like umeclidinium for COPD maintenance therapy, particularly when combined with LABAs for enhanced bronchodilation 1.
Human factors validation studies demonstrate that the Ellipta device achieves high rates of correct technique, with almost all participants (≥97%) able to complete critical tasks without error 2.